Epilepsi 2016;22(2):72-4 DOI: 10.14744/epilepsi.2015.97269

CASE REPORT / OLGU SUNUMU

A Case of Delusion During Epilepsy Treatment Following Lamotrigine Add-On

Epilepsi Tedavisi Sırasında Lamotrijin Ekleme ile Ortaya Çıkan Sanrılar

Dr. Murat Eren Özen

Murat Eren ÖZEN,[1] Musrafa ÇELİK,[2] Aysun KALENDEROĞLU[2]

[1]Özel Adana Hastanesi, Psikiyatri Kliniği, Adana
[2]Adıyaman Üniversitesi, Psikiyatri Kliniği, Adıyaman

Summary

Epilepsy may appear in comorbidity with other neurological disorders. Nevertheless, epileptic seizures and antiepileptic drugs may be responsible for the development of cognitive dysfunctions and mental disorders. Some epileptic seizures may develop with mood disorders, including depressive symptoms. Described in the present report is the case of a 23-year-old male patient with an 8-year history of partial epilepsy and a familial history of bipolarity. He had been treated for partial-onset seizures with carbamazepine and oxcarbazepine, and lamotrigine (LTG) was gradually added to treat depressive symptoms, reaching a twice-daily dosage of 100 mg. The patient developed paranoid delusions involving his neighbors, delusions which subsided after dosage was decreased to 150 mg/day. Seizure control was good, and psychiatric symptoms resolved when the dosage was decreased. Psychotic episodes resulting from rapid increase in LTG serum level has been documented.

Keywords: Acute psychosis; bipolar disorder; epilepsy; delusion; lamotrigine.

Özet

Epilepsi ruhsal bozukluklarla birlikte görülebilir, bununla beraber epileptik ataklar ve antiepileptik ilaçlar epilepsisi olan hastalarda bilişsel ve ruhsal bozuklukların gelişiminde sorumlu tutulabilmektadır. Bazı epileptik ataklar, depresif semptomlar dahil duygudurum bozukluklarına eşlik edebilir. Yirmi üç yaşında, sekiz yıllık parisyel başlangıçlı epilepsi öyküsü olup karbamazepin ve okskarbazepin alırken kontrolden çıkan ve kardeşinde bipolar bozukluk olan 23 yaşındaki erkek hastaya depresif semptomlarının da olması nedeniyle lamotrijin (LTG) eklenmiş ve kademeli olarak günde 2x100 mg dozuna çıkartılmış, 200 mg/g dozunda, hastada komşuları tarafından takip edildiği ve dinlendiği yönünde paranoid sanrılar çıkmış, LTG'nin 150 mg/g dozuna düşürüldüğümde psikiyatrik bulgu ve belirtiler kaybolmuştur. Lamotrijinin azaltılmasından sonraki bir hafta içinde hezeyanların hafiflemesi ve giderek kaybolması nedeniyle psikiyatrik bir tedavi planlanmadı. Literatürde bildirilen benzer olgular gibi olan bu olguda da genellikle LTG dozunun hızlı artırılması sonucunda psikotik ataklara ve pikiyatrik sunumların başlamasına neden olabileceğini ve ayrca birlikte kullanılan tedavilerin LTG serum seviyelerinde artışa neden olabileceğini düşündürmektedir.

Anahtar sözcükler: Akut psikoz; bipolar bozukluk; hezeyan; epilepsi; lamotrijin.

Intraduction

Epilepsy may appear in comorbidity with other neurological disorders. Due to interaction with antiepileptic treatment, patients with seizures may develop cognitive dysfunction and mood disorders that include depressive symptoms. [1] Lamotrigine (LTG) has been approved to treat a variety of seizure types in adults and children, including partial-onset seizures.[2] The main psychiatric guidelines highlight

© 2016 Türk Epilepsi ile Savaş Derneği
© 2016 Turkish Epilepsy Society

Submitted *(Geliş)*: 19.03.2015
Accepted *(Kabul)* : 11.08.2015
Correspondence *(İletişim)* : Dr. Murat Eren ÖZEN
e-mail *(e-posta)* : drmuraterenozen@gmail.com

the considerable usefulness of the drug as mood stabilizer for the treatment of patients with bipolar disorder.[3] However, psychiatric problems have been reported in epileptic patients, or those with mental disorders, primarily bipolar disorder.[4]

Case Report

The case of a 23-year-old male patient with an 8-year history of partial-onset seizures and a sibling with bipolar disorder is described in the present report. While he experienced depressive episodes, the patient had no history of behavioral problems, psychotic features, or mental retardation. Seizures had been uncontrolled for 3 months, despite treatment of carbamazepine 2x400 mg and oxcarbazepine 2x300 mg initiated 7 years prior. LTG was added to treat accompanying depressive symptoms. Following administration of LTG 25 mg per week, dosage was increased to 100 mg twice daily, and seizures ceased. The patient's mother grew anxious about her son's fears that the neighbors were following him. Mental assessment revealed that the patient also believed the neighbors were listening to him through the walls of his home. He was diagnosed with paranoid delusions caused by LTG treatment. Delusions gradually subsided within 1 week of dosage being decreased to 150 mg per day, and no additional psychiatric treatment was needed. Informed consent was taken from the patient.

Discussion

Psychiatric problems have been reported in epileptic patients or patients with mental disorders, primarily bipolar disorder, treated with LTG. Affective switches of bipolar patients following LTG add-on has been reported, as has the resolution of symptoms following cessation of LTG without the need for additional psychiatric treatment.[5–8]

Margolese et al.[8] reported hypomanic symptoms in a patient with epilepsy who was partially responsive to bupropion after LTG add-on. It was concluded that LTG has potentiating antidepressant properties, likely through its ability to decrease glutamate release, and that it is an effective adjunctive treatment in partially responsive unipolar depression.

Matsuo et al.[9] described an epileptic patient who experienced psychotic episodes after 300 mg LTG was added to treatment and 3 others who experienced delusions after addition of 500 mg LTG. In each case, symptoms resolved after LTG treatment was ceased, without additional medical psychiatric intervention. Brandt et al.[10] reported 6 similar cases of psychotic episodes.

Martin et al.[11] also reported psychotic symptoms following addition of LTG to treatment of epilepsy, and Polselli et al.[12] reported epileptic attack with loss of consciousness, delusional thinking, auditory hallucinations, and agitation. It was suggested that by reducing glutamate release, LTG triggered acute psychosis. This risk may be higher in patients prone to psychiatric disorders, particularly those with a history of mood disorder such as bipolarity.

It has been reported that LTG may cause affective switches and acute psychotic episodes, including delusions and/or hallucinations. Some affective episodes or symptoms of depression may cause or trigger epileptic seizures, as in the present case. Psychiatric problems may occur, particularly in patients genetically vulnerable to mood disorders, due to rapid dose increases, or with changes to medication that increases LTG serum levels. These may be resolved by reduction or cessation of LTG treatment. In the present case, psychotic features occurred with rapid onset and resolved with decrease in LTG dose, in accordance with reported findings.

It is recommended that LTG be administered as slowly as possible, particularly in patients with family history of psychotic disorders, particularly bipolar disorder, and in cases of polypharmacy.

Conflict of Interest: None declared.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - M.E.Ö.; Design - M.E.Ö.; Supervision - M.E.Ö; Materials - M.E.Ö.; Data Collection and/or Processing - M.Ç.; Literature Review - A.K.; Writing - M.E.Ö., M.Ç.; Critical Review - A.K., M.Ç.

References

1. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007;369(9566):1000–15.
2. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A placebo-controlled 18-month trial of lamotrig-

ine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60(4):392–400.

3. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl):1–50.
4. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64(9):1013–24.
5. Desarkar P, Sinha VK. Lamotrigine-induced severe manic switch. Aust N Z J Psychiatry 2006;40(8):718.
6. Savas HA, Selek S, Bulbul F, Kaya MC, Savas E. Successful treatment with lamotrigine in bipolar depression: a study from Turkey. Aust N Z J Psychiatry 2006;40(5):498–500.
7. Selek S, Savas HA. Lamotrigine-induced manic switches have already been reported. Aust N Z J Psychiatry 2007;41(2):195.
8. Margolese HC, Beauclair L, Szkrumelak N, Chouinard G. Hypomania induced by adjunctive lamotrigine. Am J Psychiatry 2003;160(1):183–4.
9. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43(11):2284–91.
10. Brandt C, Fueratsch N, Boehme V, Kramme C, Pieridou M, Villagran A, et al. Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature. Epilepsy Behav 2007;11(1):133–9.
11. Martin M, Muñoz-Blanco JL, Lopez-Ariztegui N. Acute psychosis induced by lamotrigine. Epilepsia 1995;36:118
12. Polselli GM, Pennisi EM, Figà Talamanca L, Roberti R, Garelli FF, Bandinelli PL. Psychotic disorder after lamotrigine. Ital J Neurol Sci 1998;19(2):124–5.